Skip to content
Open in App
Daiichi Sankyo ADR logo

Daiichi Sankyo ADR

web2

Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan and int...

Symbol · DSNKY
Company profile

About

Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan and internationally. The company offers Enhertu for the treatment of HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule for colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3, as well as symptomatic TGCT; Vanflyta, a FLT3 inhibitor for the treatment of acute myeloid leukemia; Injectafer, a ferric carboxymaltose injection for the treatment of iron deficiency; and Datroway for the treatment of HR positive and HER2 negative breast cancer, as well as NSCLC. It also provides Lixiana and Savaysa, which are direct factor Xa inhibitors; Minnebro, Olmetec, Olmetec Plus, Rezaltas, Sevikar, and Sevikar HCT, which are antihypertensive agents; Nilemdo that lowers cholesterol; Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe that reduces cholesterol; and Efient, an anti-platelet agent. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgality for the treatment of migraine attacks; Pralia for the treatment of osteoporosis and bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications and GCTB; Tarlige for the treatment of neuropathic pain; Venofer for the treatment of iron deficiency anemia; Vimpat, an anti-seizure medication; and Reyvow for the treatment of acute migraine attacks. Further, it provides Daichirona, a coronavirus RNA vaccine; Flumist, an intranasal live attenuated influenza vaccine; adsorbed cell culture-derived influenza vaccine; measles rubella combined vaccine; and mump vaccine. The company was formerly known as Sankyo Co. Ltd. and changed its name to Daiichi Sankyo Company, Limited in September 2005. Daiichi Sankyo Company, Limited was founded in 1899 and is headquartered in Chuo, Japan.

Explore by sector

Explore this sector

Market identity

Exchange listings

Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.

Progress

Roadmap

Enhertu approved in China for neoadjuvant HER2 positive breast cancer

KEY STEP

On March 27, 2026, China approved Enhertu followed by THP for neoadjuvant treatment of adults with high risk stage II or stage III HER2 positive breast cancer. The approval was based on DESTINY Breast11 phase 3 results and marked the first approval of a HER2 directed antibody drug conjugate in this neoadjuvant setting.

Enhertu approved in the US for two HER2 positive early breast cancer indications

KEY STEP

On May 15, 2026, the FDA approved Enhertu for two separate indications in adults with HER2 positive early breast cancer. The approvals cover Enhertu followed by THP as neoadjuvant treatment for stage II or stage III disease and Enhertu as adjuvant treatment for patients with residual invasive disease following prior neoadjuvant therapy.

Roadmap reference

Enhertu plus pertuzumab approved in EU for first line HER2 positive metastatic breast cancer

KEY STEP

On September 1, 2026, the European Commission approved Enhertu in combination with pertuzumab for first line treatment of adult patients with unresectable or metastatic HER2 positive breast cancer. The approval followed the July 23 CHMP positive opinion and was based on DESTINY Breast09 phase 3 results.

Roadmap reference
People

Company team

TN

Takaaki Nishii

Independent Outside Chairperson

Company leadership profile.

HO

Hiroyuki Okuzawa

President, CEO & Representative Director

Company leadership profile.

TM

Takashi Matsumoto

Sr. Exec Ofcr, Chief Corp Affairs Ofcr, Head of Global Corp Affairs & HR, CHRO & Director

Company leadership profile.

JK

Joseph Kenneth Keller

Head of Oncology Business Unit & Global Oncology Business and Director

Company leadership profile.

SM

Stuart Mackey

Global Head of Business Development & Director

Company leadership profile.

SU

Shizuko Ueno

Senior Executive Officer, Head of Japan Business Unit & Director

Company leadership profile.

MA

Miyuki Arai

Chairperson Member of Audit & Supervisory Board

Company leadership profile.

YH

Yo Honma

Independent Outside Director

Company leadership profile.

AH

Akihiro Hiroshi Watanabe

Independent Outside Director

Company leadership profile.

YK

Yasuhiro Komatsu

Independent Outside Director

Company leadership profile.

RK

Reiko Kinoshita

Independent Outside Director

Company leadership profile.

MW

Masako Watanabe

Outside Audit & Supervisory Board Member

Company leadership profile.

TY

Terumichi Yokoyama

Audit & Supervisory Board Member

Company leadership profile.

TM

Takashi Murata

Outside Audit & Supervisory Board Member

Company leadership profile.

ST

Sayuri Tago

Outside Audit & Supervisory Board Member

Company leadership profile.

Expert coverage

1 expert evaluated Daiichi Sankyo ADR.

Orbitrum research

Experts evaluating Daiichi Sankyo ADR

Explore the public profiles of experts who have evaluated this project.

Orbitrum Academy

Learn how to read a project assessment